Sodium-glucose co-transporter 2 inhibition and acute myocardial infarction: the DAPA-MI and EMPACT-MI trials

Expert Rev Clin Pharmacol. 2024 Sep;17(9):771-775. doi: 10.1080/17512433.2024.2390921. Epub 2024 Aug 12.

Authors

Muhammad Adnan Zaman¹, Sidra Kalsoom²

Affiliations

¹ Internal Medicine Department, Conemaugh Health System, Johnstown, PA, USA.
² Cardiology Department, Mercy Health Saint Vincent Medical Center, Toledo, OH, USA.

PMID: 39114881
DOI: 10.1080/17512433.2024.2390921

No abstract available

Keywords: Cardiology; DAPA-MI Trial; EMPACT-MI Trial; SGLT2 inhibitors; acute myocardial infarction; dapagliflozin; empagliflozin.

Publication types

Editorial

MeSH terms

Benzhydryl Compounds / administration & dosage
Benzhydryl Compounds / adverse effects
Benzhydryl Compounds / pharmacology
Clinical Trials as Topic
Glucosides / administration & dosage
Glucosides / adverse effects
Glucosides / pharmacology
Humans
Hypoglycemic Agents / administration & dosage
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / pharmacology
Myocardial Infarction* / drug therapy
Sodium-Glucose Transporter 2 Inhibitors* / administration & dosage
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology

Substances

Sodium-Glucose Transporter 2 Inhibitors
empagliflozin
dapagliflozin
Benzhydryl Compounds
Glucosides
Hypoglycemic Agents